Literature DB >> 17006361

Factors affecting survival of uncemented total hip arthroplasty in patients 50 years or younger.

S R Kearns1, B Jamal, C H Rorabeck, R B Bourne.   

Abstract

Providing a long-lasting total hip arthroplasty for patients younger than 50 years remains one of the greatest challenges for modern arthroplasty surgery. We retrospectively reviewed 221 patients younger than 50 years who underwent 299 uncemented total hip arthroplasties from 1983 to 2000. We assessed 5- to 15-year survival with revision as the endpoint. Femoral stem survival was 99.3% (range, 98.4-100%), 98.9% (range, 97.7-100%), and 96.8% (92.5-100%) at 5, 10, and 15 years, respectively. Including all component designs acetabular survival was 98.7% (range, 97.4-100%), 84.6% (78.8-90.4%), and 52.5% (40.7-64.3%) at 5, 10, and 15 years, respectively. Overall survival was 46.8% (33.5-58.1%) at 15 years. Total hip arthroplasties performed for hip dysplasia had lower 10-year and 15-year survival. Zirconium-on-polyethylene articulations had lower acetabular revision rates compared with cobalt-chrome-on-polyethylene. Sixty-nine revisions were performed, most commonly for polyethylene wear. Uncemented femoral stems resulted in 90% survival at 15 years followup in patients younger than 50 years at index operation. Contemporary bearing surfaces in association with such stems may provide long-lasting total hip arthroplasties, even in young, active patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006361     DOI: 10.1097/01.blo.0000238868.22852.dd

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

1.  Subcapital correction osteotomy for malunited slipped capital femoral epiphysis.

Authors:  Lucas A Anderson; Jeremy M Gililland; Christoper E Pelt; Christopher L Peters
Journal:  J Pediatr Orthop       Date:  2013-06       Impact factor: 2.324

2.  The effect of total hip replacement on employment in patients with ankylosing spondylitis.

Authors:  Chongru He; Xiaokang He; Wenwen Tong; Wei Zheng; Tianfang Zhang; Jinzhu Zhao; Weidong Xu
Journal:  Clin Rheumatol       Date:  2016-10-12       Impact factor: 2.980

3.  Alumina-on-alumina total hip arthroplasty in young patients: diagnosis is more important than age.

Authors:  Eduardo Garcia-Rey; Ana Cruz-Pardos; Eduardo Garcia-Cimbrelo
Journal:  Clin Orthop Relat Res       Date:  2009-06-04       Impact factor: 4.176

4.  Alumina-on-alumina hip arthroplasty in patients younger than 30 years old.

Authors:  R Nizard; D Pourreyron; A Raould; D Hannouche; L Sedel
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

5.  A cementless elastic monoblock socket in young patients: a ten to 18-year clinical and radiological follow-up.

Authors:  Dean Pakvis; Liesbeth Biemond; Gijs van Hellemondt; Maarten Spruit
Journal:  Int Orthop       Date:  2010-09-05       Impact factor: 3.075

6.  Total hip arthroplasty in patients 55 years or younger: Risk factors for poor midterm outcomes.

Authors:  Mohamad J Halawi; David Brigati; William Messner; Peter J Brooks
Journal:  J Clin Orthop Trauma       Date:  2017-02-09

Review 7.  Risk factors for revision of primary total hip arthroplasty: a systematic review.

Authors:  Julian Jz Prokopetz; Elena Losina; Robin L Bliss; John Wright; John A Baron; Jeffrey N Katz
Journal:  BMC Musculoskelet Disord       Date:  2012-12-15       Impact factor: 2.362

8.  Mean 5-year clinical and radiographic outcomes of cementless total hip arthroplasty in patients under the age of 30.

Authors:  Jeremy M Gililland; Lucas A Anderson; Jill Erickson; Christopher E Pelt; Christopher L Peters
Journal:  Biomed Res Int       Date:  2013-06-24       Impact factor: 3.411

9.  Revision rate of THA in patients younger than 40 years depends on primary diagnosis - a retrospective analysis with a minimum follow-up of 10 years.

Authors:  Stefan Rahm; Armando Hoch; Timo Tondelli; Johannes Fuchs; Patrick O Zingg
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-01-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.